CN-121975940-A - Use of MIGA as target in screening or preparing medicament for treating colorectal cancer

Abstract

The invention belongs to the technical fields of biological medicine and molecular biology, and particularly relates to an application of MIGA < 2 > serving as a target spot in screening or preparing a medicine for treating colorectal cancer. The invention analyzes the relativity of MIGA to colorectal cancer progress through big-queue bioinformatics, analyzes the influence of MIGA on proliferation, migration and invasion capacity of colorectal cancer cells from an in-vitro cell model, analyzes the key molecular mechanism of MIGA for playing a cancer inhibiting function, analyzes the influence of MIGA on colorectal cancer tumor growth in an in-vivo mouse model, analyzes the influence of MIGA 2-mediated mitochondria-endoplasmic reticulum contact on colorectal cancer tumor growth, and verifies that MIGA can become an effective treatment target of colorectal cancer through multiple dimensions.

Inventors

• XU LINGNA
• DAI SHENG
• CHEN YIYI

Assignees

• 浙江大学

Dates

Publication Date

20260505

Application Date

20260330

Claims (6)

1. 1. Use of a substance that increases MIGA gene or protein in the preparation of a kit for diagnosing colorectal cancer or determining prognosis.
2. 2. Use of MIGA a target molecule in screening or preparing a medicament for treating colorectal cancer.
3. 3. Use of a substance for increasing MIGA's 2 expression in the preparation of a medicament for the treatment of colorectal cancer.
4. 4. The use according to claim 3, wherein the agent that increases MIGA2 expression is a MIGA over-expression vector that increases the expression level or activity of MIGA gene and/or protein.
5. 5. A method for screening a medicament for preventing and/or treating colorectal cancer, comprising the steps of: s1, adding a substance to be detected into a detection system in a test group; s2, detecting the expression level of MIGA genes and/or proteins in a detection system of the test group, and comparing with a negative control group; S3, if the substance to be detected can promote the expression level of MIGA genes and/or proteins to be increased, the substance to be detected is a medicament for preventing and/or treating colorectal cancer.
6. 6. The method of claim 5, wherein the detection system is colorectal cancer cells.

Description

Use of MIGA as target in screening or preparing medicament for treating colorectal cancer Technical Field The invention belongs to the technical fields of biological medicine and molecular biology, and particularly relates to an application of MIGA < 2 > serving as a target spot in screening or preparing a medicine for treating colorectal cancer. Background Colorectal cancer, one of the high-frequency digestive tract malignant tumors, has been a major public health problem threatening human health with its incidence continuously rising in recent years. At present, a systematic treatment scheme combining a molecular targeting drug based on chemotherapy is widely applied to clinical practice aiming at advanced colorectal cancer and metastatic colorectal cancer, and achieves a certain treatment effect, and meanwhile, tumor immunotherapy represented by immune checkpoint inhibitors also shows good application prospects in part of patients. However, the clinical treatment still generally faces the key challenges of chemotherapy drug resistance, no immune treatment response and the like, so that the treatment effect of a considerable proportion of patients is poor and the prognosis is poor. Therefore, the exploration of novel therapeutic strategies and key action targets to improve the clinical outcome of refractory colorectal cancer patients is a core scientific problem currently in urgent need of solution in this field. Disclosure of Invention The invention aims to solve the technical problems that the existing clinical treatment scheme of colorectal cancer still has the key challenges of chemotherapy drug resistance, no response of immunotherapy and the like, and the defects of poor treatment effect and poor prognosis of a considerable proportion of patients are caused. In order to solve the technical problems, the invention provides an application of MIGA < 2 > serving as a target spot in screening or preparing medicines for treating colorectal cancer. The invention analyzes the relativity of MIGA to colorectal cancer progress through big-queue bioinformatics, analyzes the influence of MIGA on proliferation, migration and invasion capacity of colorectal cancer cells from an in-vitro cell model, analyzes the key molecular mechanism of MIGA for playing a cancer inhibiting function, analyzes the influence of MIGA on colorectal cancer tumor growth in an in-vivo mouse model, analyzes the influence of MIGA 2-mediated mitochondria-endoplasmic reticulum contact on colorectal cancer tumor growth, and verifies that MIGA can become an effective treatment target of colorectal cancer through multiple dimensions. The invention solves the technical problems through the following technical proposal. The invention provides an application of MIGA gene or protein in preparing a kit for diagnosing colorectal cancer or judging prognosis. The invention provides an application of MIGA serving as a target in screening or preparing a medicament for treating colorectal cancer. The invention provides an application of a substance for improving MIGA expression in preparing a medicament for treating colorectal cancer. In the present invention, the agent that increases MIGA expression is an agent that increases the expression level or activity of MIGA gene and/or protein. In the invention, the substance capable of improving MIGA2 expression is MIGA2 over-expression vector. In the present invention, the over-expression vector is a lentiviral vector, a plasmid vector or an adenovirus vector. In the invention, the over-expression vector is a plasmid vector. The invention provides a method for screening medicines for preventing and/or treating colorectal cancer, which comprises the following steps: s1, adding a substance to be detected into a detection system in a test group; S2, detecting the expression level of MIGA genes and/or proteins in a detection system of the test group, and comparing with a negative control group; S3, if the substance to be detected can promote the expression level of MIGA genes and/or proteins to be increased, the substance to be detected is a medicament for preventing and/or treating colorectal cancer. In the invention, the detection system is colorectal cancer cells. On the basis of conforming to the common knowledge in the field, the above preferred conditions can be arbitrarily combined to obtain the preferred examples of the invention. The reagents and materials used in the present invention are commercially available. Compared with the prior art, the invention has the beneficial effects that the invention provides the application of MIGA serving as a target spot in screening or preparing the medicament for treating colorectal cancer. The invention analyzes the relativity of MIGA to colorectal cancer progress through big-queue bioinformatics, analyzes the influence of MIGA on proliferation, migration and invasion capacity of colorectal cancer cells from an in-vitro cell model, analyzes the key molecular mechani